Company
Roche
114 published works
Big Molecule Watch
Genentech and Biocon Settle Pertuzumab Biosimilar BPCIA Litigation
On October 14, 2026, the U.S. District Court for the District of New Jersey entered an order dismissing without prejudice all claims in Genentech Inc. and Hoffmann-La Roche Inc.’s BPCIA litigation…
Garrigues | Intellectual Property Blog
The patentability of AI-assisted diagnostic methods: traditional challenges in a new context
By Garrigues
The application of AI to medical diagnosis is attracting growing interest from an industrial property perspective. In Europe, these inventions need to overcome two separate hurdles: the exclusion of certain…
Big Molecule Watch
Dualitas Therapeutics and Roche Enter Research Collaboration to Discover and Develop Bispecific Antibodies
On September 17, 2026, Dualitas Therapeutics, Inc. (“Dualitas”) announced a research collaboration and license agreement with Roche to advance novel bispecific antibodies (“BsAbs”) for immunology and inflammation diseases, using Dualitas’…
Harness Dickey Blog
Before You Sign: The IP Due-Diligence Guide for M&A and Private-Equity Deals
A practical primer on the intellectual-property questions that move deal value In many deals, the intellectual property is the asset. Software, patents, brands, and trade secrets often carry…
Spicy IP
‘Venetoclax’ at the IPO: Why Generics Need More than Patent Refusals
How much of a win is a patent rejection for domestic generics production? In this post, I discuss the specific points of IPO’s refusal as a continuation of Indian patent…
Big Molecule Watch
Celltrion Announces AVTOZMA (tocilizumab-anoh) Now Available in U.S.
On March 16, 2026, Celltrion, Inc. announced the U.S. commercial launch of AVTOZMA® (tocilizumab-anoh) SC, a subcutaneous formulation of its tocilizumab biosimilar referencing Roche’s ACTEMRA. Celltrion had previously launched its…
Roberts Disability Law Blog
Ninth Circuit Upholds Dismissal of ERISA Fiduciary Breach Claims Against Genentech
In Wehner v. Genentech, Inc., No. 24-2630, 2025 WL 2505672 (9th Cir. Sept. 2, 2025), the Ninth Circuit affirmed the dismissal of ERISA claims brought by a former Genentech employee…
Big Molecule Watch
European Commission Approves Celltrion’s AVTOZMA (CT-P47)
On February 23, 2025, Celltrion announced that the European Commission (“EC”) approved its tocilizumab biosimilar, AVTOZMA® (CT-P47), referencing Roche’s ROACTEMRA®. Tocilizumab is a monoclonal antibody that acts as an interleukin-6 (IL-6)…
Zalma on Insurance
CEO Used Money From Company & Its Insurers to Defend Criminal Conduct
By Barry Zalma
Conviction of Wire Fraud Requires Defendant to Repay Funds Advanced by Employer and Insurers Post 4852 See the full video at https://rumble.com/v5a72zh-ceo-used-money-from-company-and-its-insurers-to-defend-criminal-conduct.html?mref=22lbp&mrefc=2 and at https://youtu.be/GL3WDZWfhso Defendant Dr. W. Scott Harkonen…
Big Molecule Watch
Biogen’s TOFIDENCE (tocilizumab) Approved in the EU
This week, Biogen announced that the European Commission has approved TOFIDENCE, a tocilizumab biosimilar referencing Roche’s ROACTEMRA. TOFIDENCE was approved by the FDA in September 2023. TOFIDENCE is an intravenous…